Glucagonoma
ICD-10 E16.3 · ICD-11 2E92.9&XH4NQ8

Treatment of Small (<2 cm) Resectable Peripheral Glucagonoma of the Pancreatic Head or Distal Pancreas

Clinical Scenario

This protocol addresses the uncommon presentation of a glucagonoma that is small (<2 cm) and peripherally located in the head or distal pancreas, where surgical resection is feasible. Small peripheral glucagonomas are rare and carry distinct management considerations compared to larger or unresectable tumors.

Specific Situation

Small (<2 cm) peripheral glucagonomas of the pancreatic head or distal pancreas are rare. When anatomically suitable, enucleation or local excision with peripancreatic lymph dissection may be considered. Preoperative medical optimisation — including blood glucose control and attention to the hypercoagulable state associated with glucagonoma — is an important part of the preparation for surgery.

Treatment Approach (Partial Overview)

Management involves a somatostatin analog for symptom and tumor control in the period leading up to surgery. Blood glucose must be adequately managed before the procedure. Given the elevated thrombotic risk associated with this tumor type, anticoagulation is considered perioperatively. Surgical excision follows, with lymph node assessment.

Full sequencing, drug selection, dosing, and individualised considerations are in the complete protocol.

Treatment Goals

Blood glucose control Resolution of flushing Resolution of diarrhea Resolution of dermatitis
Instant Access to Structured Evidence-Based Regimens

References

  1. Small (<2 cm) peripheral glucagonomas are rare; enucleation or local excision with peripancreatic lymph dissection may be considered for small peripheral tumors of the head or distal pancreas.
  2. For symptom and/or tumor control, octreotide LAR or lanreotide every 4 weeks. Higher doses have been shown to be safe. For breakthrough symptoms, octreotide SC TID can be considered.
  3. For patients with glucagonoma, treatment of hyperglycemia and diabetes is necessary, especially to control blood sugar level prior to surgery.
  4. A hypercoagulable state has been reported in 10% to 33% of patients with glucagonoma. Therefore, perioperative anticoagulation can be considered because of the increased risk of pulmonary emboli.
View source ↗